Q2 report due 15 August '24e-'26e EBITA down 5-1%; 9% CAGR '23-'26e 10-6x EBITA '24e-'26e, 11-15% FC...
Redeye retains its positive view of Fortnox. While management should have clarified it was talking a...
Biovica records IVD test sales in Q4, which are higher than Q1-Q3, and research test sales have incr...
Bolaget utökar antalet kliniker i fas 2-studien med läkemedelskandidaten Lipisense efter en smärre f...
Redeye comments on Artificial Solutions' directed rights issue, which was announced after the market...
Redeye provides a comment on the outcome in Scandinavian ChemoTech’s rights issue.
Redeye comments on Verve’s acquisition of Jun Group, which strengthens its position on the demand si...
We expect the negative growth trend to continue in Q2 Good cost control is protecting profitability ...
CoinShares International (CS) is a pioneer and a well-established player in the nascent, high-growth...
Redeye comments on Fluoguide raising cSEK60m through a directed share issue.
Marknadens nedgång träffar till slut med full kraft, så ledningen revar seglen och vi sänker prognos...
Med pusselbitarna på plats accelererade lyftet för kursen i februari, men potential finns kvar i akt...
Redeye expects a Q2 report from Addnode with limited organic growth yet solid margins.
Q2e: sales +18% and EBITDA +38% y-o-y We raise our EBITDA estimates by 10-6% on '24e-'26e Positive E...
Analyst Group har med Refine Group ingått avtal om kontinuerlig analysbevakning, innefattande bl.
Under Q1-24 har Syncro Group (”Koncernen”) fortsatt att exekvera på tillväxtstrategin som lanserades...
VNV Global är investmentbolaget som ger en unik möjlighet till att få exponering mot onoterade snabb...
Redeye is encouraged by the news that Kontigo Care is launching Previct Safety—a digital drug test s...
Redeye updates its estimates for the Q2 2024 report (due 2024-07-18).
